X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (856) 856
Publication (126) 126
Book Review (17) 17
Book Chapter (5) 5
Conference Proceeding (2) 2
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ruxolitinib (822) 822
index medicus (512) 512
humans (417) 417
myelofibrosis (366) 366
hematology (323) 323
oncology (256) 256
myeloproliferative neoplasms (210) 210
female (175) 175
male (167) 167
polycythemia-vera (153) 153
mutation (145) 145
essential thrombocythemia (141) 141
middle aged (141) 141
aged (134) 134
primary myelofibrosis - drug therapy (132) 132
available therapy (122) 122
pyrazoles - therapeutic use (122) 122
therapy (118) 118
treatment outcome (109) 109
protein kinase inhibitors - therapeutic use (106) 106
survival (105) 105
janus kinase 2 - antagonists & inhibitors (99) 99
polycythemia vera (98) 98
adult (95) 95
efficacy (92) 92
animals (91) 91
international working group (90) 90
care and treatment (88) 88
primary myelofibrosis (87) 87
jak2 (86) 86
leukemia (86) 86
janus kinase 2 - genetics (80) 80
janus kinase (77) 77
aged, 80 and over (76) 76
janus kinases - antagonists & inhibitors (75) 75
pharmacology & pharmacy (73) 73
analysis (69) 69
jak2 inhibitor (67) 67
myeloid metaplasia (66) 66
tyrosine kinase jak2 (65) 65
cancer (63) 63
research (63) 63
patients (62) 62
safety (61) 61
article (60) 60
medicine & public health (60) 60
tumors (59) 59
double-blind (57) 57
mutations (56) 56
hemic and lymphatic diseases (55) 55
protein kinase inhibitors - pharmacology (55) 55
pyrazoles - pharmacology (55) 55
myeloproliferative disorders (53) 53
transplantation (53) 53
health aspects (52) 52
immunology (52) 52
splenomegaly (52) 52
stem cells (52) 52
tofacitinib (51) 51
hydroxyurea (50) 50
drug therapy (49) 49
kinases (49) 49
jak inhibitor (48) 48
janus kinase 2 (48) 48
mice (48) 48
medical research (47) 47
pyrazoles - adverse effects (47) 47
signal transduction - drug effects (47) 47
anemia (46) 46
hematology, oncology and palliative medicine (46) 46
pyrazoles - administration & dosage (46) 46
quality-of-life (46) 46
myeloproliferative neoplasm (45) 45
polycythemia vera - drug therapy (45) 45
janus kinase 1 - antagonists & inhibitors (44) 44
janus kinase 2 - metabolism (44) 44
myeloproliferative disorders - drug therapy (44) 44
prognosis (44) 44
protein kinase inhibitors - adverse effects (44) 44
medicine, experimental (43) 43
neoplasms (42) 42
bone marrow (41) 41
dermatology (41) 41
primary myelofibrosis - genetics (41) 41
quality of life (41) 41
cytokines (40) 40
polycythemia (40) 40
antineoplastic agents - therapeutic use (39) 39
primary myelofibrosis - diagnosis (39) 39
activation (38) 38
jak inhibitors (38) 38
gene expression (37) 37
genetic aspects (37) 37
abridged index medicus (36) 36
disease (36) 36
inhibitor (36) 36
interferon (36) 36
acute myeloid-leukemia (35) 35
comfort-ii (35) 35
diagnosis (35) 35
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (811) 811
German (10) 10
Russian (10) 10
Spanish (8) 8
Hungarian (5) 5
Polish (5) 5
French (4) 4
Czech (2) 2
Turkish (2) 2
Japanese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 1583 - 1583
Abstract Philadelphia-negative Myeloproliferative Neoplasms (MPN) include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis, both... 
Journal Article
Journal of Dermatological Treatment, ISSN 0954-6634, 01/2018, Volume 29, Issue 1, pp. 98 - 99
Journal Article
Science Translational Medicine, ISSN 1946-6234, 09/2014, Volume 6, Issue 255, pp. 255 - 255ec164
Journal Article
Oncotarget, ISSN 1949-2553, 08/2018, Volume 9, Issue 68, pp. 32883 - 32884
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S10 - S11
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2019, Volume 25, Issue 16, pp. 4898 - 4906
Purpose: Myelofibrosis is characterized by bone marrow fibrosis, atypical megakaryocytes, splenomegaly, constitutional symptoms, thrombotic and hemorrhagic... 
ONCOLOGY | MYELOPROLIFERATIVE NEOPLASMS | RUXOLITINIB
Journal Article
Neurology, ISSN 0028-3878, 02/2018, Volume 90, Issue 6, pp. 289 - 291
IFIH1 gain-of-function causes a spectrum of neuroinflammatory phenotypes associated with enhanced type I interferon production and Janus kinase (JAK)/signal... 
MUTATIONS | AICARDI-GOUTIERES SYNDROME | CLINICAL NEUROLOGY | RUXOLITINIB
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2019, Volume 25, Issue 16, pp. 4868 - 4870
The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery... 
ONCOLOGY | AVAILABLE THERAPY | RUXOLITINIB
Journal Article
The Journal of allergy and clinical immunology, ISSN 0091-6749, 11/2018, Volume 142, Issue 5, pp. 1665 - 1669
Treatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to... 
Ruxolitinib | Tofacitinib | STAT1 | Tocilizumab | HLH | STAT3 | Jakinib
Journal Article
Internal Medicine, ISSN 0918-2918, 2018
A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening... 
disseminated tuberculosis | primary myelofibrosis | ruxolitinib
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 32, pp. 22605 - 22617
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current chemotherapy is quite toxic in growing children and more directed... 
BCL-2 | Ruxolitinib | T-ALL | Venetoclax | JAK1
Journal Article
Blood, ISSN 0006-4971, 05/2019, Volume 133, Issue 20, pp. 2233 - 2242
Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current prognostic scoring systems aim to select patients for... 
SURVIVAL | MODELS | PROGNOSIS | MYELOPROLIFERATIVE NEOPLASMS | MUTATIONS | HEMATOLOGY | RUXOLITINIB
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 03/2014, Volume 370, Issue 12, pp. 1169 - 1169
Journal Article
Hematologia, ISSN 2081-3287, 2018, Volume 9, Issue 2, pp. 90 - 99
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 10/2019
Journal Article
ARTHRITIS & RHEUMATOLOGY, ISSN 2326-5191, 07/2017, Volume 69, Issue 7, pp. 1495 - 1501
Objective. Gain-of-function mutations in TMEM173, encoding the stimulator of interferon (IFN) genes (STING) protein, underlie a novel type I interferonopathy... 
IMMUNITY | TBK1 | IKK-EPSILON | TREX1 | DISEASE | MUTATIONS | RHEUMATOLOGY | VASCULOPATHY | RUXOLITINIB
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.